Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Date:2/13/2008

change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development (including the successful development of JUVISTA(R) (Human TGFb3)), manufacturing and commercialization (including the launch and establishment in the market of VYVANSE(TM)); the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD) and GA-GCB (Gene-Activated Glucocerebrosidane); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

---------------------------------

(1) Epsicom Business Intelligence. (June 30, 2007) The Pharmaceutical Market: Mexico


'/>"/>
SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Genzyme Receives Approval to Market Elaprase(R) in Japan
3. Clexane(R)/Lovenox(R) Approved in Japan
4. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Biomoda Announces Collaborative Agreement With New Mexico Tech
10. Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
11. Prestigious Bioethics Award for Scholar from Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014  Decision Resources Group ... , Russia , India ... approximately $1.6 billion in 2013, roughly equal to the size of ... forward, however, the BRIC market will experience much faster growth as ... the aging population. Other key findings from Decision Resources ...
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... August 19, 2014 Cellgen ... raise $200,000 to fund a corporate lab for ... , This development is a critical component in ... care to the implementation of personalized medicine – ... practicing medicine. , Indiegogo contributions will support Cellgen’s ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... SAN FRANCISCO, Calif., Nov. 1, 2010 diaDexus, Inc. ... company focused on the development and commercialization of patent-protected ... in cardiovascular disease, today announced that the company, formerly ... Bulletin Board under the ticker symbol (VXGN), has been ...
... With... -- BOZEN, Sud-Tirol, Italy, November 1, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... 30 Tibotec Pharmaceuticals (Tibotec) announced today the company will ... the phase 2 response-guided PILLAR study in treatment-naive patients with ... Annual Meeting of the American Association for the Study of ... be presented as part of a late-breaker oral presentation on ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 2Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 3Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 4Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 5Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 6Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 7Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 8Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 9Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 3Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 4
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
(Date:8/20/2014)... Area Lyme Foundation, which aims to make Lyme disease ... research published in an upcoming issue of the Elsevier ... The findings show that ticks that carry Lyme ... making the threat of Lyme disease year-round. The research ... Health (CDPH) Vector-borne Disease Section and University of California, ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... Pharmaceuticals report this week that they have successfully used RNA ... mice, an advance that could lead to new treatments for ... 1998 discovery of RNA interference the naturally occurring phenomenon ... nucleus to the protein-building machinery of the cell is disrupted ...
... New Delhi, Singapore and Washington DC (Dec 28, 2010) ... identify with political parties , according to an article in ... official journal of the Western Political Science Association (published by ... studied concepts in modern political science. Scholars have long held ...
... spotlight that illuminates an otherwise dark scene, attention brings to ... A new study by researchers at the Salk Institute for ... that primarily had been known for its role in the ... the mind,s spotlight. Their findings, published in the Dec. ...
Cached Biology News:New RNA interference technique can silence up to 5 genes 2Seeing without looking 2
... Trap Time of Flight Mass Analyzer for superior sensitivity, mass accuracy, ... - 25,000 m/z, * Precursor ion selection range: 150 - 4000 ... 5 ppm with internal reference, * Dynamic range: 4 orders of ... ...
... pYD1 Yeast Display Vector is specifically designed ... the surface of Saccharomyces cerevisiae. Displayed proteins ... interact with known or putative ligands. pYD1 ... consists of two domains, Aga1 and Aga2, ...
... Oncostatin M (OSM) is a pleiotropic ... and Kaposis sarcoma cells. OSM inhibits the ... lines, simulates fibroblast, smooth muscle and Kaposis ... cells and low density lipoprotein receptor expression ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
Biology Products: